AMRX vs EOLS
AMRX: Amneal Pharmaceuticals is a diversified biopharma company providing a broad range of essential, affordable generic and specialty medicines, alongside pharmaceutical distribution services. EOLS: A global performance beauty company specializing in injectable aesthetic products, primarily botulinum toxin (Jeuveau®) and hyaluronic acid gels (Evolysse™), for the direct-pay medical aesthetics market.
Side-by-side fundamentals
| Metric | AMRX | EOLS | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $18.09 | $6.18 | |
| Market cap as of 2026-07-29 | $5.8B | $405M | |
| P/E as of 2026-07-29 | 48.50 | n/a | |
| PEG as of 2026-07-29 | 2.57 | n/a | |
| Net margin as of 2026-07-29 | +4.0% | -14.4% | AMRX higher |
| Gross margin as of 2026-07-29 | +38.7% | +66.1% | EOLS higher |
| Operating margin as of 2026-07-29 | +14.3% | -8.1% | AMRX higher |
| ROE as of 2026-07-29 | -34.9% | -410.2% | AMRX higher |
| ROA as of 2026-07-29 | +3.4% | -19.4% | AMRX higher |
| Debt / equity as of 2026-07-29 | 136.58 | 22.00 | EOLS lower |
| Revenue growth (YoY) as of 2026-07-29 | +7.6% | +9.6% | EOLS higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | +26.0% | EOLS higher |
| Beta as of 2026-07-29 | 1.25 | 1.39 | |
| 1-year return as of 2026-07-27 close | +124.4% | -35.2% | AMRX higher |
Fundamentals: Finnhub, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.